aplastic anemia | Page 45 | Aplastic Anemia & MDS International Foundation

aplastic anemia

Cotransplantation of allogeneic mesenchymal and hematopoietic stem cells in children with aplastic anemia

Author(s): 
Wang H, Yan H, Wang Z, Zhu L, Liu J, Guo Z
Primary Author: 
Wang H
Journal Title: 
Pediatrics
Original Publication Date: 
May 2012

We report here the preliminary results of allogeneic hematopoietic stem cell transplantation with mesenchymal

Bone Marrow Diseases: 

Immunosuppressive Therapy in Aplastic Anemia.

Author(s): 
Gupta V, Kumar A, Tilak V, Saini I, Bhatia B.
Primary Author: 
Gupta V
Journal Title: 
Indian J Pediatr.
Original Publication Date: 
Jan 2012

OBJECTIVE:

To assess the response to antithymocyte globulin based immunosuppressive therapy (IST) in pediatric patients with idiopathic aplastic anemia.
METHODS:

Thirty patients (19 boys and 11 girls) with aplastic anemia received antithymocyte globulin and cyclosporine. Twenty-two patients had severe and 8 had very severe aplastic anemia.
RESULTS:

Bone Marrow Diseases: 

Bone marrow versus peripheral blood sibling transplants in acquired aplastic anemia: survival advantage for marrow in all age groups.

Author(s): 
Bacigalupo A, Socie' G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuhrer M, Risitano A, Dufour C, Passweg J, Oneto R, Aljurf M, Flynn C, Mialou V, Hamladji RM, Marsh J.
Primary Author: 
Bacigalupo A
Journal Title: 
Haematologica
Original Publication Date: 
Feb 2012

Background.

Bone Marrow Diseases: 

HLA-Matched Sibling Transplantation for Severe Aplastic Anemia: Impact of HLA DR15 Antigen Status on Engraftment, Graft-versus-Host Disease, and Overall Survival.

Author(s): 
Battiwalla M, Wang T, Carreras J, Deeg HJ, Ayas M, Bajwa RP, George B, Gupta V, Pasquini R, Schrezenmeier H, Passweg JR, Schultz KR, Eapen M.
Primary Author: 
Battiwalla M
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
Feb 2012

The HLA class II DRB1 antigen DR15 (common alleles *1501, *1502) is an important marker in the pathobiology of severe

Bone Marrow Diseases: 

Rabbit-antithymocyte globulin combined with cyclosporin A as a first-line therapy: improved, effective, and safe for children with acquired severe aplastic anemia.

Author(s): 
Chen C, Xue HM, Xu HG, Li Y, Huang K, Zhou DH, Guo HX, Fang JP, Huang SL.
Primary Author: 
Chen C
Journal Title: 
J Cancer Res Clin Oncol
Original Publication Date: 
Mar 2012

PURPOSE:

Acquired aplastic anemia is an organ-specific auto-immune disease characterized by pancytopenia and hypoplastic bone marrow. Immunosuppression with anti-thymocyte globulin (ATG) and cyclosporine A (CsA) is an effective and safe therapy for patients without undergoing hematopoietic stem cell transplantation. The aim of the current study was to investigate the effect of rabbit-ATG (r-ATG) combined with CsA as an intensive immunosuppressive therapy (IST) for acquired severe aplastic anemia (SAA) in children.
METHODS:

Bone Marrow Diseases: